Daniel Wilson to Heptanoic Acids
This is a "connection" page, showing publications Daniel Wilson has written about Heptanoic Acids.
Connection Strength
0.564
-
Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial. Stroke. 2014 Oct; 45(10):2974-82.
Score: 0.110
-
Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study). Am J Cardiol. 2012 Jun 15; 109(12):1761-6.
Score: 0.093
-
Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis. 2009 May; 53(5):741-50.
Score: 0.075
-
Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. Am J Hypertens. 2009 Feb; 22(2):137-44.
Score: 0.074
-
Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc. 2008 Aug; 83(8):870-9.
Score: 0.072
-
Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008 Apr 15; 51(15):1448-54.
Score: 0.071
-
Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007 Nov; 2(6):1131-9.
Score: 0.068